Renaissance Technologies
GPCR icon

Renaissance Technologies’s Structure Therapeutics GPCR Stock Holding History

Renaissance Technologies’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-55,800
Closed -$2.69M – 3359
2026
Q1 		$2.69M Sell
55,800
-59,400
-52% -$4.07M ﹤0.01% 1718
2025
Q4 		$8.01M Sell
115,200
-38,700
-25% -$1.58M 0.01% 1035
2025
Q3 		$4.31M Buy
153,900
+42,000
+38% +$837K 0.01% 1587
2025
Q2 		$2.32M Buy
111,900
+96,100
+608% +$2.11M ﹤0.01% 2023
2025
Q1 		$273K Buy
+15,800
New +$387K ﹤0.01% 2960
2024
Q3 		– Sell
-35,700
Closed -$1.4M – 3663
2024
Q2 		$1.4M Buy
+35,700
New +$1.47M ﹤0.01% 2112
2023
Q3 		– Sell
-32,900
Closed -$1.37M – 3830
2023
Q2 		$1.37M Buy
+32,900
New +$922K ﹤0.01% 2250

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Renaissance Technologies's GPCR Position: Q2 2026 in Review

Renaissance Technologies sold out of Structure Therapeutics (GPCR) in Q2 2026, closing a stake of 55,800 shares — an estimated $2.69M sold.

Renaissance Technologies first reported a position in GPCR in Q2 2023 and held it in 7 quarters. The position peaked at $8.01M in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Renaissance Technologies reported no remaining Structure Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Renaissance Technologies sold 55,800 Structure Therapeutics shares in Q2 2026, an estimated $2.69M.
  • Renaissance Technologies first reported a position in Structure Therapeutics in Q2 2023 and held it in 7 quarters.
  • Renaissance Technologies's Structure Therapeutics position peaked at $8.01M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.